In short
This article discusses a clinical trial investigating the use of Furosemide Ph. Eur., a loop diuretic, for goal-directed fluid removal in critically ill patients with fluid overload. The study, known as the GODIF trial, aims to assess the benefits and potential risks of using Furosemide compared to a placebo in adult ICU patients with moderate to severe fluid accumulation.
At a glance
- Trial Name
- GODIF (Goal directed fluid removal in critically ill patients with fluid overload)
- Drug Studied
- Furosemide Ph. Eur. (loop diuretic)
- Main Objective
- Assess benefits and harms of goal-directed fluid removal with Furosemide vs. placebo in ICU patients with fluid overload
- Primary Endpoint
- Number of days alive and out of hospital at day 90
- Key Inclusion Criteria
- Adult ICU patients with fluid accumulation ≥5% of ideal body weight
- Key Exclusion Criteria
- Allergy to Furosemide, advanced kidney disease, ongoing renal replacement therapy
- Drug Administration
- Intravenous infusion, max daily dose 1500 mg, max total dose 135,000 mg
- Treatment Duration
- Up to 3 months
What is Furosemide?
Furosemide (also known as FUROSEMIDE PH. EUR.) is a medication that belongs to a class of drugs called loop diuretics. Loop diuretics are medications that help your body get rid of excess fluid by increasing urine production. Furosemide is commonly used in medical settings, particularly in intensive care units (ICUs), to treat patients with fluid overload.
Medical Conditions Treated by Furosemide
Furosemide is primarily used to treat fluid overload or fluid accumulation. Fluid overload is a condition where there is too much fluid in the body, which can lead to swelling, breathing difficulties, and other health problems. This condition can occur in various situations, including:
- Heart failure
- Kidney problems
- Liver disease
- Certain lung conditions
- After major surgery
- In critically ill patients in the ICU
How Furosemide Works
Furosemide works by helping your kidneys remove excess fluid from your body. It does this by:
- Increasing urine production
- Promoting the excretion of salt (sodium and chloride) and water
- Reducing fluid buildup in tissues, which can help decrease swelling
By removing excess fluid, furosemide can help improve symptoms associated with fluid overload, such as shortness of breath and swelling in the legs and ankles.
How Furosemide is Administered
In the clinical trial described, furosemide is administered through intravenous infusion. This means the medication is given directly into a vein through a small tube called an IV. Intravenous administration allows the medication to work quickly and is often used in hospital settings, especially for patients in the ICU.
Dosage Information
The dosage of furosemide can vary depending on the individual patient's needs and condition. In the clinical trial mentioned, the following dosage information is provided:
- Maximum daily dose: 1500 mg
- Maximum total dose: 135,000 mg
- Maximum treatment period: 3 months
It's important to note that these doses are specific to the clinical trial and may not reflect typical dosing in other medical situations. Always follow your healthcare provider's instructions regarding medication dosage.
Current Clinical Trial: GODIF
A clinical trial called GODIF (Goal Directed Fluid Removal) is currently being conducted to study the effects of furosemide in critically ill patients with fluid overload. The main objective of this trial is to determine if using furosemide to remove excess fluid can improve patient outcomes compared to allowing the body to remove fluid naturally (placebo group).
Eligibility Criteria for the GODIF Trial
To participate in the GODIF trial, patients must meet specific criteria. These include:
- Acute admission to the ICU
- 18 years of age or older
- Clinically stable condition (as assessed by doctors)
- Fluid accumulation of at least 5% of ideal body weight
There are also several conditions that would exclude a patient from participating in the trial, such as known allergy to furosemide, severe kidney or liver problems, and certain other medical conditions.
Potential Benefits and Outcomes
The GODIF trial aims to assess several important outcomes for patients treated with furosemide, including:
- Number of days alive and out of the hospital at 90 days after treatment
- Overall survival rate at 90 days and 1 year
- Days alive without needing life support
- Quality of life after 1 year
- Cognitive function after 1 year
These outcomes will help researchers understand the potential benefits and risks of using furosemide for fluid removal in critically ill patients with fluid overload.